Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Hackshaw

Showing results (71-80 of 166) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|February 18, 2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trialRobert Glynne-Jones, David Sebag-Montefiore, Helen M Meadows, et al.
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
Cardio-Oncology (London, England)|April 1, 2025
Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort studyFu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinomaOz Kilim, Orsolya Pipek, Zsofia Sztupinszki, et al.
International Journal of Environmental Research and Public Health|February 15, 2022
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in HealthcareDenis Horgan, Bettina Borisch, Ivana Cattaneo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2019
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapySiow Ming Lee, Sunil Upadhyay, Conrad Lewanski, et al.
Journal of Medical Screening|March 1, 2021
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trialAmanda J Cross, Jonathan Myles, Paul Greliak, et al.
Nature|August 13, 2025
Clone copy number diversity is linked to survival in lung cancerPiotr Pawlik, Kristiana Grigoriadis, Abigail Bunkum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Keyue Ding, Siow Ming Lee, et al.
Pageof 17

Showing results (71-80 of 166) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|February 18, 2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trialRobert Glynne-Jones, David Sebag-Montefiore, Helen M Meadows, et al.
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
Cardio-Oncology (London, England)|April 1, 2025
Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort studyFu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinomaOz Kilim, Orsolya Pipek, Zsofia Sztupinszki, et al.
International Journal of Environmental Research and Public Health|February 15, 2022
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in HealthcareDenis Horgan, Bettina Borisch, Ivana Cattaneo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2019
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapySiow Ming Lee, Sunil Upadhyay, Conrad Lewanski, et al.
Journal of Medical Screening|March 1, 2021
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trialAmanda J Cross, Jonathan Myles, Paul Greliak, et al.
Nature|August 13, 2025
Clone copy number diversity is linked to survival in lung cancerPiotr Pawlik, Kristiana Grigoriadis, Abigail Bunkum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Keyue Ding, Siow Ming Lee, et al.
Pageof 17